Adocia SA (EPA:ADOC)

France flag France · Delayed Price · Currency is EUR
4.918
+0.274 (5.90%)
Apr 28, 2026, 5:35 PM CET
26.75%
Market Cap 90.99M
Revenue (ttm) 3.85M
Net Income (ttm) -16.59M
Shares Out 19.59M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 435,770
Average Volume 279,860
Open 4.650
Previous Close 4.644
Day's Range 4.624 - 5.040
52-Week Range 3.300 - 12.400
Beta 0.25
RSI 47.68
Earnings Date Apr 21, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combinati... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 77
Stock Exchange Euronext Paris
Ticker Symbol ADOC
Full Company Profile

Financial Performance

In 2025, Adocia's revenue was 3.85 million, a decrease of -68.26% compared to the previous year's 12.12 million. Losses were -16.59 million, 78.0% more than in 2024.

Financial Statements

News

There is no news available yet.